Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 4/24/25 → 4/24/27 |
Funding
- Deciphera Pharmaceuticals LLC: $2.00
24-HEM-21-DP (DCC-3014-02-001): A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
- Yalniz, Fevzi (PI)